Afrocab shared a letter from about 200 advocates that shares our concern regarding the slow pace at which the important drug Cabotegravir – Long-Acting (CAB-LA) is made accessible to all who need it.
We welcome Dr Nkengasong’s leadership in engaging key stakeholders, including the originator manufacturer ViiV Healthcare, policy-makers, such as WHO and national governments, and communities most at risk of HIV infection, to remove all access barriers.
The letter can be found here
-
Membership of AfroCAB is free and open to HIV-positive people and community advocates.
Meetings
AfroCAB meetings are free and limited to 30 people. Meetings are interactive, with questions, discussions and time to network. Meetings are held in various locations within Africa.
Pages
- Home
- AfroCAB activities by country
- AFROCAB members at INTEREST conference
- @afrocab_hiv and #TAG are excited to share a call for a new cross-disease long-acting technologies (LAT) community advisory board (CAB) focused on #malaria, the #HepC virus and #LTBI for a 4year tenure, 2021-2024. Deadline 1st June 2021!
- Board Members
- AHD Graphics to share!
- About AfroCAB
- Contact AfroCAB
- Join the AfroCAB
- Meetings
- Resources
- AfroCAB members